Diagnosing and Treating All Stages of Neurotrophic Keratitis: Online Case Theater (CME Webcast)
Activity Description and Purpose
Optimal outcomes in patients with neurotrophic keratitis (NK), a progressively damaging corneal disease, require a timely and accurate diagnosis and effective treatment that heals and reinnervates the corneal epithelium. Diagnosis and treatment of NK can be challenging because of a symptom and sign profile that overlaps with that of other ocular diseases, such as dry eye disease; its concomitant presence with other ocular or systemic diseases, such as glaucoma and diabetes; and a lack of patients reporting symptoms due to reduced sensation in the cornea. The following case theater features 4 real-life examples of all stages of NK, along with discussions on diagnosis and treatment.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Review the pathophysiology of neurotrophic keratitis
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
- Select treatment strategies for patients diagnosed with any stage of neurotrophic keratitis
Marjan Farid, MD
Anthony J. Aldave, MD
Karolinne M. Rocha, MD, PhD
Christopher E. Starr, MD, FACS
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Anthony J. Aldave, MD, is a consultant for Avellino Labs, ClearView Healthcare Partners, Dompé US, Inc, Gerson Lehrman Group, Inc, GlaxoSmithKline, Guidepoint, Health Advances LLC, LEK Consulting, Presbia PLC, and W. L. Gore & Associates, Inc; and receives honoraria from CorneaGen.
Marjan Farid, MD, is a consultant for Allergan, Bausch & Lomb Incorporated, Bio-Tissue, CorneaGen, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Zeiss.
Karolinne M. Rocha, MD, PhD, is a consultant for Dompé US, Inc.
Christopher E. Starr, MD, is a consultant for Aerie Pharmaceuticals, Inc, Aldeyra Therapeutics, Allergan, BlephEx, Bruder Healthcare, Dompé US, Inc, Èssiri Labs, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Oculis, Oyster Point Pharma, Inc, Quidel Corporation, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, and Visionology; and has stock options in Èssiri Labs and Visionology.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dompé US, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.
This CME activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 255
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation